Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. - Wikidata - awgldk - TriplyDB

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

http://www.wikidata.org/entity/Q37283073

about

Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review.Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis The discovery and development of sorafenib for the treatment of thyroid cancer.Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study Pazopanib: therapeutic developments.Sorafenib Induced Hand Foot Skin Rash in FLT3 ITD Mutated Acute Myeloid Leukemia-A Case Report and Review of Literature.Toxicity of sorafenib: clinical and molecular aspects.Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma.Sorafenib-associated hand-foot syndrome in Japanese patients.Sorafenib in melanoma.The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.The adverse effects of sorafenib in patients with advanced cancers.Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma.PharmGKB summary: sorafenib pathways.Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.Risk Factors Exacerbating Hand-Foot Skin Reaction Induced by Capecitabine plus Oxaliplatin with or without Bevacizumab Therapy.Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma.Array of cutaneous adverse effects associated with sorafenib Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS).Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.

P2860

Q27335748-1E7F9A0B-5028-469E-A606-418A0C957A5D Q28482219-F79F1F9E-3374-465F-8BB4-F24ECAD0A11A Q30250106-6D3E41A5-6E35-466C-BD7B-21F1D847C260 Q33408049-84BE0669-A531-48CD-83E6-133FD263AB95 Q34036032-58709D18-231B-462B-8452-D6096AE5A6A6 Q34042709-AD383850-FE88-4D96-BA66-8BD93E91866F Q34363435-BA610CF2-A2F2-45BC-A15B-292242B57B11 Q34973732-9FDD51F0-9B37-4CC0-9162-62C8992333BD Q35104052-5F27365D-254D-4FCC-B87C-3DF33A75014D Q35419004-527F6EB8-FA45-474E-9D48-BBA61EDF0D12 Q35553882-48AC5E72-5356-4C18-AD87-72F8C26E094A Q35599769-939E8833-E217-4629-A27B-AD407982A0B2 Q35891218-9F05125F-D465-40F1-AA13-97F02C58CB91 Q36078348-B4C0311E-C530-4FBD-8EC6-53981E635147 Q36112023-39615203-7629-4A54-9901-09D7986012A7 Q36251480-F0B16989-D25C-4642-925C-E7C721AC7287 Q36263304-40BD9AA9-0271-4196-A106-8D46C8B7757D Q36525237-31832070-B7CF-439B-853F-875AD304DC4D Q36528151-1310EFF0-3BD6-44F4-A838-34F2DDD5586F Q37152133-25F15226-3EFE-479D-8E18-77D6A5122C7D Q37642770-946BB9BC-BC5C-48E3-B363-5D4BEF8A46EF Q37663028-B7710385-C014-45F4-8B5A-E19C68953DAB Q37676226-E50944D7-6956-4AE6-B024-445E6396D4B9 Q37683755-483A78E3-79FF-4964-BDA2-5570555D76E6 Q37845916-E5835E9C-393E-4C01-8698-093D94992AF9 Q37990977-073ECA12-D494-4791-9C75-2C3CDD27DF4C Q38076349-DC029F35-7965-4F4D-8B05-B19AA8CBF31E Q38201503-307971DC-6050-40D3-8666-7E0DB9BFF8A0 Q38286308-5FDF8237-85BE-4EC5-9E2F-683A0A3698CB Q38368008-798965B3-D4CA-44AD-BBB6-ED7A91477142 Q38864682-FBDF2EA2-D3EB-4C73-B776-C5330D02E5EC Q38886929-097F88E9-516E-4B27-AC4E-809E04B75FCF Q39320160-D33F2475-BB5F-4EAF-AFEA-6B9139589703 Q39379568-E2F17F5A-0088-4223-AFFB-380150930A92 Q39555847-2ACC231B-7483-4536-8ACB-68F573D4B3F1 Q40751962-B1A5AE3C-B9B5-4794-A152-1F9CEA02EDC3 Q41229554-553527A4-4391-47BB-BFE8-52DF8EF86081 Q42556141-82A9E0FF-10F3-426F-AF7C-1ED7BE40AE89 Q44252023-316FFBDE-C7FB-4120-B4B1-76230D0444D5 Q45766668-9BE23DBD-4834-4EF8-B016-48EED548E76C

P2860

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

http://www.wikidata.org/entity/Q37283073

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Hand-foot skin reaction increa ...... thelial growth factor therapy.

@en

Hand-foot skin reaction increa ...... thelial growth factor therapy.

@nl

type

label

Hand-foot skin reaction increa ...... thelial growth factor therapy.

@en

Hand-foot skin reaction increa ...... thelial growth factor therapy.

@nl

prefLabel

Hand-foot skin reaction increa ...... thelial growth factor therapy.

@en

Hand-foot skin reaction increa ...... thelial growth factor therapy.

@nl

P1433

Q37283073-42F7AF0D-5D34-4C75-84AB-9BAE39ACB924

P1476

Q37283073-5851CCBA-2353-4AF1-99B9-A7C6F0128FC0

P2093

Q37283073-3279B6E5-4713-473F-A2D3-57D63199BF93

Q37283073-3722A93B-AF6C-4DF7-8FD4-C0AFC110D721

Q37283073-5785CB44-DBE2-4FAD-BD38-59A4D0AFE895

Q37283073-760D50D7-F294-4D5D-9BA8-AEDF046735D4

Q37283073-AEB7CC76-155E-432C-AFD7-B891744307F5

Q37283073-AF8FED43-501E-42FA-8053-1632B8DE0FA0

Q37283073-E58791FB-6C5A-4910-B694-69F9FD23EF2F

Q37283073-ED08017C-68CE-4263-900B-E6B6E5CD475F

P2860

Q37283073-16454DEE-46A7-475F-85E9-2A16560D368E

Q37283073-205DDCC4-2246-4AC9-A436-751B01117B82

Q37283073-24F40F84-7EBA-4DD9-96AB-1B95CD76C5D9

Q37283073-26CD2806-EB2B-49E2-8BF9-987CBDCE26E5

Q37283073-2E44B5E3-19CE-4B0E-9CC4-1A079E9FD360

Q37283073-4269C98B-F2C6-4895-9F93-17578CD4E65F

Q37283073-54F75E0F-9F93-40A9-93E6-3BAFE253E69C

Q37283073-65BA1454-42AC-4D89-83D2-844CC3D04AC9

Q37283073-662CAB5A-8117-493A-8CB0-A87E03654A05

Q37283073-69FBB312-AA4B-427F-AC52-5E615A7DDDED

P304

Q37283073-63B01161-7E4D-4298-B861-6A17FDCAE57B

P31

Q37283073-29823709-B9E9-42DA-86D2-E67E0DD1428C

P356

Q37283073-2BD766AD-8D97-4875-B146-87123900C140

P407

Q37283073-579EC688-4456-4799-9106-02E9603EE5BE

P433

Q37283073-7FF997D0-63B1-454F-BABC-3647FAB56C78

P478

Q37283073-6043FDBD-54CC-4483-8991-C47CA8AFEEDC

P50

Q37283073-49A552A6-0A92-4B7A-9AA8-23E1D892935F

Q37283073-853ECAC7-B4CE-4AA9-AE94-5D51FEA02E75

P577

Q37283073-E513BAFF-8E15-4C69-B91F-8AFC4B210828

P5875

Q37283073-CE26DE0B-FA89-488D-8C03-94EBFDB0A53A

P698

Q37283073-875698C7-AF86-49B9-B41E-6975D2B8A5D3

P921

Q37283073-A81E63C1-B893-468F-9DC0-89850FE19E05

P932

Q37283073-7AF1FF89-A8D5-41EF-B2A3-0F9B8FC60940

P356

1078-0432.CCR-08-1141

P1433

Clinical Cancer Research

P1476

Hand-foot skin reaction increa ...... othelial growth factor therapy

@en

P2093

Elise C Kohn

http://www.w3.org/2001/XMLSchema#string

Lokesh Jain

http://www.w3.org/2001/XMLSchema#string

Maria L Turner

http://www.w3.org/2001/XMLSchema#string

Martin Gutierrez

http://www.w3.org/2001/XMLSchema#string

Nilofer S Azad

http://www.w3.org/2001/XMLSchema#string

Seth M Steinberg

http://www.w3.org/2001/XMLSchema#string

William D Figg

http://www.w3.org/2001/XMLSchema#string

William L Dahut

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced clear-cell renal-cell carcinoma

Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome.

Keratoacanthomas associated with sorafenib therapy.

Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.

P304

1411-1416

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-1141

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Jeanny B Aragon-Ching

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24026635

http://www.w3.org/2001/XMLSchema#string

P698

19228742

http://www.w3.org/2001/XMLSchema#string

P921

P932

2718558

http://www.w3.org/2001/XMLSchema#string